Woodline Partners’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.52M | Sell |
|
|||||
|
2025
Q2 | $5.24M | Sell |
|
|||||
|
2025
Q1 | $7.55M | Sell |
|
|||||
|
2024
Q4 | $11.8M | Buy |
|
|||||
|
2024
Q3 | $14.3M | Buy |
|
|||||
|
2024
Q2 | $2.39M | Sell |
|
|||||
|
2024
Q1 | $4.11M | Sell |
|
|||||
|
2023
Q4 | $3.62M | Sell |
|
|||||
|
2023
Q3 | $3.2M | Buy |
|
|||||
|
2023
Q2 | $4.49M | Buy |
|
|||||
|
2023
Q1 | $3.91M | Sell |
|
|||||
|
2022
Q4 | $10.8M | Buy |
|
|||||
|
2022
Q3 | $4.29M | Buy |
|
|||||
|
2022
Q2 | – | Sell |
|
|||||
|
2022
Q1 | $293K | Sell |
|
|||||
|
2021
Q4 | $3.29M | Buy |
|
|||||
|
2021
Q3 | $4.24M | Buy |
|
|||||
|
2021
Q2 | $11.7M | Buy |
|
|||||
|
2021
Q1 | $9.02M | Sell |
|
|||||
|
2020
Q4 | $9.99M | Buy |
|